Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines

Karl S. Peggs; Stephanie Verfuerth; Arnold Pizzey; Naeem Khan; Malcolm Guiver; Paul A. Moss; Stephen Mackinnon

doi:10.1016/S0140-6736(03)14634-X

Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines

Karl S. Peggs^*, Stephanie Verfuerth, Arnold Pizzey, Naeem Khan, Malcolm Guiver, Paul A. Moss, Stephen Mackinnon

^*Corresponding author for this work

Manchester Lab Clinical Development

Research output: Contribution to journal › Article › peer-review

424 Citations (Scopus)

Abstract

Adoptive transfer of CMV-specific T cells offers the potential for reconstitution of viral immunity after allogeneic transplantation. However, the logistics of producing virus-specific T-cell clones has limited the application of cellular therapies. We treated 16 patients for CMV infection with polyclonal CMV-specific T-cell lines generated by short-term culture. Massive in-vivo expansions of CMV-specific cytotoxic T lymphocytes were observed, resulting in reconstitution of viral immunity. In eight cases antiviral drugs were not required, and subsequent episodes of reactivation occurred in only two patients. Our findings indicate that application of CMV-specific cell lines is both feasible and effective in a clinical environment.

Original language	English
Pages (from-to)	1375-1377
Number of pages	3
Journal	The Lancet
Volume	362
Issue number	9393
DOIs	https://doi.org/10.1016/S0140-6736(03)14634-X
Publication status	Published - 25 Oct 2003

Bibliographical note

Funding Information:
S Mackinnon is funded by the Leukaemia Research Fund (London, UK); K Peggs receives financial support from the Golden Charitable Trust (London, UK). The funding sources had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

Access to Document

10.1016/S0140-6736(03)14634-X

Cite this

@article{e09f6a19e065423f858910b9c96a28ce,

title = "Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines",

abstract = "Adoptive transfer of CMV-specific T cells offers the potential for reconstitution of viral immunity after allogeneic transplantation. However, the logistics of producing virus-specific T-cell clones has limited the application of cellular therapies. We treated 16 patients for CMV infection with polyclonal CMV-specific T-cell lines generated by short-term culture. Massive in-vivo expansions of CMV-specific cytotoxic T lymphocytes were observed, resulting in reconstitution of viral immunity. In eight cases antiviral drugs were not required, and subsequent episodes of reactivation occurred in only two patients. Our findings indicate that application of CMV-specific cell lines is both feasible and effective in a clinical environment.",

author = "Peggs, {Karl S.} and Stephanie Verfuerth and Arnold Pizzey and Naeem Khan and Malcolm Guiver and Moss, {Paul A.} and Stephen Mackinnon",

note = "Funding Information: S Mackinnon is funded by the Leukaemia Research Fund (London, UK); K Peggs receives financial support from the Golden Charitable Trust (London, UK). The funding sources had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.",

year = "2003",

month = oct,

day = "25",

doi = "10.1016/S0140-6736(03)14634-X",

language = "English",

volume = "362",

pages = "1375--1377",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "9393",

}

TY - JOUR

T1 - Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines

AU - Peggs, Karl S.

AU - Verfuerth, Stephanie

AU - Pizzey, Arnold

AU - Khan, Naeem

AU - Guiver, Malcolm

AU - Moss, Paul A.

AU - Mackinnon, Stephen

N1 - Funding Information: S Mackinnon is funded by the Leukaemia Research Fund (London, UK); K Peggs receives financial support from the Golden Charitable Trust (London, UK). The funding sources had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

PY - 2003/10/25

Y1 - 2003/10/25

N2 - Adoptive transfer of CMV-specific T cells offers the potential for reconstitution of viral immunity after allogeneic transplantation. However, the logistics of producing virus-specific T-cell clones has limited the application of cellular therapies. We treated 16 patients for CMV infection with polyclonal CMV-specific T-cell lines generated by short-term culture. Massive in-vivo expansions of CMV-specific cytotoxic T lymphocytes were observed, resulting in reconstitution of viral immunity. In eight cases antiviral drugs were not required, and subsequent episodes of reactivation occurred in only two patients. Our findings indicate that application of CMV-specific cell lines is both feasible and effective in a clinical environment.

AB - Adoptive transfer of CMV-specific T cells offers the potential for reconstitution of viral immunity after allogeneic transplantation. However, the logistics of producing virus-specific T-cell clones has limited the application of cellular therapies. We treated 16 patients for CMV infection with polyclonal CMV-specific T-cell lines generated by short-term culture. Massive in-vivo expansions of CMV-specific cytotoxic T lymphocytes were observed, resulting in reconstitution of viral immunity. In eight cases antiviral drugs were not required, and subsequent episodes of reactivation occurred in only two patients. Our findings indicate that application of CMV-specific cell lines is both feasible and effective in a clinical environment.

UR - http://www.scopus.com/inward/record.url?scp=0242285681&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(03)14634-X

DO - 10.1016/S0140-6736(03)14634-X

M3 - Article

C2 - 14585640

AN - SCOPUS:0242285681

SN - 0140-6736

VL - 362

SP - 1375

EP - 1377

JO - The Lancet

JF - The Lancet

IS - 9393

ER -

Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this